NCT00445978
Sickle Cell Disease
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This Phase 2a, multicenter, open-label, dose-escalation study is designed to assess the safety and biologic activity of daily oral administration of 4 escalating doses of sapropterin dihydrochloride over 16 weeks in subjects with sickle cell disease. During an optional extension phase, the study will assess the safety, tolerability, and efficacy of extended treatment with sapropterin dihydrochloride, for a total of up to 2 years; The extension phase of this study was terminated.
All
From 15 Years
No
Sapropterin Dihydrochloride
Phase 2
Interventional
32
2007-05
2021-02-25
Washington, District of Columbia, United States
Augusta, Georgia, United States
Savannah, Georgia, United States
Indianapolis, Indiana, United States
Detroit, Michigan, United States
Flint, Michigan, United States
Hackensack, New Jersey, United States
Chapel Hill, North Carolina, United States
Philadelphia, Pennsylvania, United States
Galveston, Texas, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields